# ![@JCO_ASCO Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2395900849.png) @JCO_ASCO Journal of Clinical Oncology

Journal of Clinical Oncology posts on X about in the, factor, editor, stage the most. They currently have [------] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: undefined [#](/creator/twitter::2395900849/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:interactions.svg)

- [--] Week [-----] +21%
- [--] Month [-----] +54%
- [--] Months [------] +8.20%
- [--] Year [------] +179%

### Mentions: undefined [#](/creator/twitter::2395900849/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:posts_active.svg)


### Followers: [------] [#](/creator/twitter::2395900849/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:followers.svg)

- [--] Week [------] +0.09%
- [--] Month [------] +0.33%
- [--] Months [------] +2.10%
- [--] Year [------] +5.60%

### CreatorRank: undefined [#](/creator/twitter::2395900849/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  [countries](/list/countries)  [stocks](/list/stocks)  [travel destinations](/list/travel-destinations)  [social networks](/list/social-networks)  [technology brands](/list/technology-brands) 

**Social topic influence**
[in the](/topic/in-the), [factor](/topic/factor), [editor](/topic/editor), [stage](/topic/stage), [article](/topic/article), [history](/topic/history), [events](/topic/events), [solid](/topic/solid), [art](/topic/art), [dr](/topic/dr)

**Top assets mentioned**
[Hologic, Inc. (HOLX)](/topic/hologic-inc) [Mantle (MNT)](/topic/mantle) [Frontline Ltd. (FRO)](/topic/$fro)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Editorial: A visitor's perspective on cancer care in the rural United States #JCOOP https://fal.cn/3967k https://fal.cn/3967k"  
[X Link](https://x.com/JCO_ASCO/status/1281695946389291009)  2020-07-10T21:05Z 55.1K followers, [--] engagements


"🤔 Minimal Residual Disease not associated with progression-free survival outcomes after fixed-duration Ibrutinib-Venetoclax vs Chlorambucil-Obinutuzumab in the GLOW study in #ChronicLymphocyticLeukemia ➡ #CLL #Leusm https://fal.cn/3zGGt https://fal.cn/3zGGt"  
[X Link](https://x.com/JCO_ASCO/status/1677059914160537601)  2023-07-06T21:00Z 54.9K followers, 24.2K engagements


"Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort [--] Results. Read the full article. https://brnw.ch/21wWtWe https://brnw.ch/21wWtWe"  
[X Link](https://x.com/JCO_ASCO/status/1976271909458182434)  2025-10-09T13:01Z 54.8K followers, [----] engagements


"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial. Co-authored by @Mohty_EBMT. Read the full article. https://brnw.ch/21wWS46 https://brnw.ch/21wWS46"  
[X Link](https://x.com/JCO_ASCO/status/1981345090669809814)  2025-10-23T13:00Z 54.9K followers, [----] engagements


"177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label Randomized Controlled Phase II Study. Read the full article. https://brnw.ch/21wXQRd https://brnw.ch/21wXQRd"  
[X Link](https://x.com/JCO_ASCO/status/1993726702225133579)  2025-11-26T17:01Z 55K followers, [----] engagements


"The first-ever Phase III randomized showdown is here See results of pirtobrutinib vs. ibrutinib in treatment-nave and R/R patients. Is the non-covalent BTKi the game-changer weve waited for #ASH25 simultaneous publication with Woyach et al. is LIVE: https://brnw.ch/21wYbdz https://brnw.ch/21wYbdz"  
[X Link](https://x.com/JCO_ASCO/status/1998071374569443519)  2025-12-08T16:45Z 55.1K followers, [----] engagements


"Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NonSmall Cell Lung Cancer: Results From CHRYSALIS-2. Read the full article. #LungCancer #lcsm #SCLC https://brnw.ch/21wYAtb https://brnw.ch/21wYAtb"  
[X Link](https://x.com/JCO_ASCO/status/2003466089972342950)  2025-12-23T14:01Z 55.2K followers, [----] engagements


"Reply to: FOLFIRINOX for Locally Advanced Pancreatic Cancer Conversion Chemo for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine and Chemo for Locally Advanced Pancreatic Cancer: The Dilemma of David vs Goliath After NEOPAN." https://brnw.ch/21wYJEZ https://brnw.ch/21wYJEZ"  
[X Link](https://x.com/JCO_ASCO/status/2006138365544894562)  2025-12-30T23:00Z 55.2K followers, [----] engagements


"Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology episode "Final Silence by Dr. Ju Won Kim who confronts the burden of silence in the care of the dying. Tune in with host @MikkaelSekeres: https://brnw.ch/21wZ1wZ https://brnw.ch/21wZ1wZ"  
[X Link](https://x.com/JCO_ASCO/status/2010759329247289827)  2026-01-12T17:02Z 55.2K followers, [----] engagements


"Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade NonMuscle-Invasive Bladder Cancer. Read the full article. https://brnw.ch/21wZ2Zt https://brnw.ch/21wZ2Zt"  
[X Link](https://x.com/JCO_ASCO/status/2011076119370367475)  2026-01-13T14:01Z 55.2K followers, [----] engagements


"North Star: a luminous gut-honest reflection by a pediatric oncologist reminding us that beyond protocols and outcomes the deepest medicine is presence. Read the full article. https://brnw.ch/21wZ3S9 https://brnw.ch/21wZ3S9"  
[X Link](https://x.com/JCO_ASCO/status/2011211788671394034)  2026-01-13T23:00Z 55.2K followers, [---] engagements


"Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer Read the full article. #NSCLC https://brnw.ch/21wZ5OR https://brnw.ch/21wZ5OR"  
[X Link](https://x.com/JCO_ASCO/status/2011528903957840017)  2026-01-14T20:00Z 55.2K followers, [----] engagements


"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia. Read the full article. https://brnw.ch/21wZ63h https://brnw.ch/21wZ63h"  
[X Link](https://x.com/JCO_ASCO/status/2011574318698819741)  2026-01-14T23:01Z 55.2K followers, [----] engagements


"Methodological and Reporting Gaps in the SURF Trial. Read the full article. https://brnw.ch/21wZ75N https://brnw.ch/21wZ75N"  
[X Link](https://x.com/JCO_ASCO/status/2011801153151930638)  2026-01-15T14:02Z 55.2K followers, [---] engagements


"Reply to: Blind Spots in REZILIENT-1: Does Post-platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ NonSmall Cell Lung Cancer Co-authored by @ZPiotrowskaMD. Read the full article. #NSCLC https://brnw.ch/21wZ7Pe https://brnw.ch/21wZ7Pe"  
[X Link](https://x.com/JCO_ASCO/status/2011891359112638714)  2026-01-15T20:00Z 55.2K followers, [---] engagements


"Reply to: Revisiting Methodological Paradigms in Local Therapies for HCC: Insights from the SURF study and "Methodological and Reporting Gaps in the SURF Trial." Read the full article. https://brnw.ch/21wZ9kk https://brnw.ch/21wZ9kk"  
[X Link](https://x.com/JCO_ASCO/status/2012208546104893545)  2026-01-16T17:01Z 55.2K followers, [----] engagements


"The Power of I Don't Know.' A reflection by @SondosZayedMD on how honest uncertainty can deepen trust guide care and create space for what truly matters in oncology. Read the full Art of Oncology article. https://brnw.ch/21wZh04 https://brnw.ch/21wZh04"  
[X Link](https://x.com/JCO_ASCO/status/2014020806074896547)  2026-01-21T17:02Z 55.3K followers, [---] engagements


"Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study. Co- authored by @ChiaraCrem1 and @VeroKonk. Read the full article. https://brnw.ch/21wZj0I https://brnw.ch/21wZj0I"  
[X Link](https://x.com/JCO_ASCO/status/2014383848839094601)  2026-01-22T17:05Z 55.3K followers, [----] engagements


"Building a sustainable multiple myeloma program in Western Kenya #mmsm #JCOGO https://fal.cn/3eqKP https://fal.cn/3eqKP"  
[X Link](https://x.com/JCO_ASCO/status/1377652492763328518)  2021-04-01T16:02Z 55.3K followers, [--] engagements


"Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era Co-authored by @VivekSubbiah. Read the full article. https://brnw.ch/21wZszj https://brnw.ch/21wZszj"  
[X Link](https://x.com/JCO_ASCO/status/2016512037778583831)  2026-01-28T14:01Z 55.3K followers, [----] engagements


"Timing Is of the Essence: Sequencing Immune Checkpoint Blockade and Radiotherapy for Success in Lung Cancer. Read the full article. #LungCancer #lcsm https://brnw.ch/21wZtyT https://brnw.ch/21wZtyT"  
[X Link](https://x.com/JCO_ASCO/status/2016647619284480420)  2026-01-28T23:00Z 55.3K followers, [----] engagements


"Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials. Read the full article. #LungCancer #lcsm #btsm https://brnw.ch/21wZDbS https://brnw.ch/21wZDbS"  
[X Link](https://x.com/JCO_ASCO/status/2018776864001531933)  2026-02-03T20:01Z 55.4K followers, [----] engagements


"Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2Positive Breast Cancer. Read the full article. #BreastCancer #bcsm https://brnw.ch/21wZTso https://brnw.ch/21wZTso"  
[X Link](https://x.com/JCO_ASCO/status/2021993505808109579)  2026-02-12T17:03Z 55.4K followers, [----] engagements


"Dr. Dawn Hershman (@DrDawnHershman) Honored With the [----] Hologic Inc Endowed Women Who #ConquerCancer Mentorship Award #ASCODailyNews @ConquerCancerFd https://fal.cn/384It https://fal.cn/384It"  
[X Link](https://x.com/JCO_ASCO/status/1260917850123964417)  2020-05-14T13:00Z 52.6K followers, [--] engagements


"#JCO's [----] impact factor rose to [------] the highest in the history of the Journal and placing it in the top 1% of all journals https://fal.cn/3940T https://fal.cn/3940T"  
[X Link](https://x.com/anyuser/status/1281197159145263104)  2020-07-09T12:03Z 55.4K followers, [--] engagements


"Radiation Oncology Services and Practice in Jordan #JCOGO https://fal.cn/3960m https://fal.cn/3960m"  
[X Link](https://x.com/JCO_ASCO/status/1281660720145465347)  2020-07-10T18:45Z 53.9K followers, [--] engagements


"Less is more 🤔 2-cycle cisplatin concurrent chemoradiotherapy is not inferior to 3-cycles based on 3-yr PFS in treating locoregionally advanced nasopharyngeal ca w/preRX EBV DNA levels 4000.QOL & toxicity improved w/ less chemo https://fal.cn/3lBWk https://fal.cn/3lBWk"  
[X Link](https://x.com/JCO_ASCO/status/1485998408104091648)  2022-01-25T15:30Z 53K followers, [--] engagements


"📈 AERAS: Postoperative adjuvant anastrozole for [--] years VS [--] years in pts w/ hormone receptor-positive #BreastCancer improved disease free survival but not overall survival #BCSM ➡ https://fal.cn/3ytyL https://fal.cn/3ytyL"  
[X Link](https://x.com/JCO_ASCO/status/1661084660066140160)  2023-05-23T19:00Z 52.9K followers, [----] engagements


"✨ #JCO #ClinicalTrialUpdates: Pazopanib+chemoradiation+surgery in patients with soft tissue #sarcoma did not improve outcomes 👉 #surgonc #radonc #NRGOnc #scmsm https://brnw.ch/21wC8Or https://brnw.ch/21wC8Or"  
[X Link](https://x.com/JCO_ASCO/status/1697040780228018178)  2023-08-31T00:17Z 52.6K followers, [----] engagements


"📣 #JCO #Editorial: Chemoimmunotherapy for untreated #LungCancer brain metastases: Systemic before local therapy #LCSM #ImmunoOnc @Benjamin_Y_Lu @NadalErnest"  
[X Link](https://x.com/JCO_ASCO/status/1710716627744878902)  2023-10-07T18:00Z 48.9K followers, [----] engagements


"🥳 Read the Art of Oncology Special Edition With more than [--] years' worth of essays re-read the stories that speak to the mission of oncology care address ethical challenges and honor patients. 👉 @l_schapira https://brnw.ch/21wDlOx https://brnw.ch/21wDlOx"  
[X Link](https://x.com/JCO_ASCO/status/1711440645368221928)  2023-10-09T17:57Z 52.5K followers, [----] engagements


"💙 Read Art of Oncology's special edition With over [--] years of essays re-read the stories that speak to the mission of oncology care address ethical challenges and honor patients: @l_schapira #OncTwitter"  
[X Link](https://x.com/JCO_ASCO/status/1711470592686268506)  2023-10-09T19:56Z 48.9K followers, [----] engagements


"🙌 Featured in Best of #JCO Hematologic Malignancies edition: Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated #MantleCellLymphoma ➡ #lymsm"  
[X Link](https://x.com/JCO_ASCO/status/1735098533315784923)  2023-12-14T00:45Z 48.9K followers, [----] engagements


"🙌 Featured in Best of #JCO Hematologic Malignancies edition: Daratumumab Cyclophosphamide Bortezomib Lenalidomide and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk #MultipleMyeloma ➡ @MyMKaiser #mmsm"  
[X Link](https://x.com/JCO_ASCO/status/1735389199203749979)  2023-12-14T20:00Z 48.9K followers, [----] engagements


"🚨 Check out #JCOs latest paper: Lisocabtagene Maraleucel in Relapsed/Refractory #MantleCellLymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL [---] a Phase I Multicenter Seamless Design Study ➡ #lymsm"  
[X Link](https://x.com/JCO_ASCO/status/1735661061284470904)  2023-12-15T14:00Z 48.8K followers, [----] engagements


"#ASCO24 simultaneous publication by Williams et al: CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced #NSCLC: https://brnw.ch/21wKnSd https://brnw.ch/21wKnSd"  
[X Link](https://x.com/JCO_ASCO/status/1797600394391986221)  2024-06-03T12:05Z 51K followers, [----] engagements


"Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors: @MikeFooteMD #gicsm https://brnw.ch/21wLYNy https://brnw.ch/21wLYNy"  
[X Link](https://x.com/JCO_ASCO/status/1826298347126178106)  2024-08-21T16:40Z 52.6K followers, [----] engagements


"Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive #ProstateCancer From the Phase III ARANOTE Trial: #pcsm https://brnw.ch/21wN25s https://brnw.ch/21wN25s"  
[X Link](https://x.com/anyuser/status/1838201865277780380)  2024-09-23T13:00Z 55.4K followers, [----] engagements


"Glofitamab in Relapsed/Refractory Mantle Cell #Lymphoma: Results From a Phase I/II Study @LymphClinican #lymsm https://brnw.ch/21wNE2K https://brnw.ch/21wNE2K"  
[X Link](https://x.com/JCO_ASCO/status/1844402768385044951)  2024-10-10T15:41Z 52.5K followers, [----] engagements


"Association of Participation in Medicares Oncology Care Model With Spending Utilization and Quality Outcomes Among Commercially Insured and Medicare Advantage Members: @ravi_b_parikh @samyuktaMD https://brnw.ch/21wNG8x https://brnw.ch/21wNG8x"  
[X Link](https://x.com/JCO_ASCO/status/1844739988212040136)  2024-10-11T14:01Z 52.5K followers, [----] engagements


"Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo) Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Position Emission Tomography/Compu. Tomography in Stage [--] Non-Small Cell #LungCancer https://brnw.ch/21wNPd2 https://brnw.ch/21wNPd2"  
[X Link](https://x.com/JCO_ASCO/status/1846555912682586390)  2024-10-16T14:16Z 52.5K followers, [----] engagements


"Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the [------] #Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice @EllieMcDonagh @QMUL @GenomicsEngland @emblebi https://brnw.ch/21wOrN0 https://brnw.ch/21wOrN0"  
[X Link](https://x.com/JCO_ASCO/status/1854509529293099503)  2024-11-07T13:01Z 52.5K followers, [----] engagements


"Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large #BCellLymphoma: Phase [--] Experience From the ALPHA2/ALPHA Clinical Studies: #lymsm https://brnw.ch/21wQUQA https://brnw.ch/21wQUQA"  
[X Link](https://x.com/JCO_ASCO/status/1894055059710726543)  2025-02-24T16:01Z 52.8K followers, [----] engagements


"Listen to the inaugural episode of ASCO Education: By the Book. This episode features @n8pennell of @ClevelandClinic & Dr. Don Dizon of @BrownUniversity reflecting on the evolution of the #ASCOEducationalBook & highlight the launch its companion podcast ➡ http://brnw.ch/21wRZAJ http://brnw.ch/21wRZAJ"  
[X Link](https://x.com/JCO_ASCO/status/1911904773479014493)  2025-04-14T22:09Z 53.1K followers, [----] engagements


"Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label Multicenter Randomized Controlled Clinical Trial. Read full article. https://brnw.ch/21wSckb https://brnw.ch/21wSckb"  
[X Link](https://x.com/JCO_ASCO/status/1915436193971372076)  2025-04-24T16:02Z 54.7K followers, [----] engagements


"Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase InhibitorPretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) @jeff_sharman #leusm #lymsm https://brnw.ch/21wTktH https://brnw.ch/21wTktH"  
[X Link](https://x.com/JCO_ASCO/status/1932875272933593454)  2025-06-11T18:59Z 53.8K followers, [----] engagements


"Listen to #JCOs Cancer Stories: The Art of Oncology podcast episode "A Whipple of Choice by Dr. Carl Forsberg who shares his experience with an uncommon cancer treated by new therapy which no direct relevant data was available. @DrSGraff @MikkaelSekeres https://brnw.ch/21wTHVW https://brnw.ch/21wTHVW"  
[X Link](https://x.com/JCO_ASCO/status/1938267451180917135)  2025-06-26T16:05Z 53.9K followers, [----] engagements


"Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass OpacityDominant Lung Adenocarcinoma. Read the full article. https://brnw.ch/21wUqiZ https://brnw.ch/21wUqiZ"  
[X Link](https://x.com/JCO_ASCO/status/1948730775878209604)  2025-07-25T13:03Z 54.2K followers, 11.7K engagements


"TAR-200 for Bacillus Calmette-GurinUnresponsive High-Risk NonMuscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. Co-authored by @siadaneshmand. Read the full article. https://brnw.ch/21wUHTZ https://brnw.ch/21wUHTZ"  
[X Link](https://x.com/JCO_ASCO/status/1953078890840080413)  2025-08-06T13:01Z 54.5K followers, [----] engagements


"Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor SN38 (DEP-SN38): Safety Tolerability and Preliminary Efficacy Study in Patients With Advanced Solid Tumors. Co-authored by @JiaJennyLiu. Read the full article. https://brnw.ch/21wUJQU https://brnw.ch/21wUJQU"  
[X Link](https://x.com/JCO_ASCO/status/1953441358674338133)  2025-08-07T13:01Z 54.7K followers, [----] engagements


"Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. Co-authored by @ManuPalmerini. Read the full article. #sarcoma https://brnw.ch/21wV5Xv https://brnw.ch/21wV5Xv"  
[X Link](https://x.com/JCO_ASCO/status/1958560166049202627)  2025-08-21T16:01Z 54.3K followers, [----] engagements


"KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn Read the full article. #gicsm https://brnw.ch/21wVaQI https://brnw.ch/21wVaQI"  
[X Link](https://x.com/JCO_ASCO/status/1959964484019105948)  2025-08-25T13:02Z 54.4K followers, [----] engagements


"TAR-200 for Bacillus Calmette-GurinUnresponsive High-Risk NonMuscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. Co-authored by @siadaneshmand. Read the full article. #blcsm https://brnw.ch/21wVoLx https://brnw.ch/21wVoLx"  
[X Link](https://x.com/JCO_ASCO/status/1962869532378165456)  2025-09-02T13:25Z 54.5K followers, [----] engagements


"Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence. Read the full article. #BreastCancer #bcsm https://brnw.ch/21wWk1l https://brnw.ch/21wWk1l"  
[X Link](https://x.com/JCO_ASCO/status/1974097551117656243)  2025-10-03T13:01Z 54.7K followers, [----] engagements


"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. Co-authored by @malignantheme and @EuniceWangMD. Read the full article. https://brnw.ch/21wWnW1 https://brnw.ch/21wWnW1"  
[X Link](https://x.com/JCO_ASCO/status/1975184633311490184)  2025-10-06T13:01Z 54.7K followers, [----] engagements


"Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma. Read the full article. https://brnw.ch/21wWokY https://brnw.ch/21wWokY"  
[X Link](https://x.com/JCO_ASCO/status/1975230253967482933)  2025-10-06T16:02Z 54.7K followers, [----] engagements


"Bridging the Gap: The Evolving Landscape of CNS Management in Small Cell Lung Cancer: Prophylactic Cranial Irradiation in the Modern Era. Co-authored by @TLChaunzwaMD. Read the full article. https://brnw.ch/21wWpLm https://brnw.ch/21wWpLm"  
[X Link](https://x.com/JCO_ASCO/status/1975547109462966592)  2025-10-07T13:01Z 54.6K followers, [----] engagements


"Submitting your study testing Artificial Intelligence (#AI) models Read new guidance from the #JCO editors: https://brnw.ch/21wWsoK https://brnw.ch/21wWsoK"  
[X Link](https://x.com/JCO_ASCO/status/1975955297551167879)  2025-10-08T16:03Z 54.7K followers, [----] engagements


"Passive scattering proton therapy versus IMRT for locally advanced NSCLC #LCSM #radonc http://bit.ly/2DiIvnR http://bit.ly/2DiIvnR"  
[X Link](https://x.com/JCO_ASCO/status/951174462870835201)  2018-01-10T19:30Z 52.6K followers, [--] engagements


"Celebrating [--] years of pioneering oncology research with @ASCO's Journal of Clinical Oncology We're thrilled to share this milestone in our history. Look forward to the reveal of our most-cited publication on 12/15. Discover the top-cited articles: https://ascopubs.org/jco/40th-anniversary https://ascopubs.org/jco/40th-anniversary"  
[X Link](https://x.com/anyuser/status/1734969237523886510)  2023-12-13T16:11Z 55.4K followers, 26.4K engagements


"🙌 Enfortumab vedotin + pembro as 1st-line tx for metastatic #UrothelialCancer yields response rate of 73.3% duration of response [----] mo overall survival [----] mo.👉 #JCO #blcsm #kcsm #gucsm @DrRosenbergMSK https://fal.cn/3sEjU https://fal.cn/3sEjU"  
[X Link](https://x.com/anyuser/status/1579931100897427456)  2022-10-11T20:25Z 55.4K followers, [---] engagements


"#JCO's [----] impact factor increased to [------] which is the highest among oncology publications and in the top 1% of all journals. https://fal.cn/3gsVk https://fal.cn/3gsVk"  
[X Link](https://x.com/anyuser/status/1410328547504365575)  2021-06-30T20:05Z 55.4K followers, [---] engagements


"No more reformatting Submit your manuscript format-free to @ASCO Journals with EZSubmit ✅ https://fal.cn/3nubO https://fal.cn/3nubO"  
[X Link](https://x.com/anyuser/status/1510754029432938497)  2022-04-03T23:00Z 55.4K followers, [---] engagements


"☢🦴 In a multi-center RCT ⚖ (n=78) radiation to high-risk asymptomatic bone metastases skeletal-related events and prolonged overall survival in metastatic solid tumors: #radonc @ErinGillespieMD https://brnw.ch/21wE43a https://brnw.ch/21wE43a"  
[X Link](https://x.com/anyuser/status/1719787162802008387)  2023-11-01T18:43Z 55.4K followers, 60.3K engagements


"@ASCO Guideline just published: Treatment of Metastatic Colorectal Cancer Read in #JCO ➡ #crcsm #mCRC https://fal.cn/3sOlo https://fal.cn/3sOlo"  
[X Link](https://x.com/anyuser/status/1582117915645874176)  2022-10-17T21:14Z 55.4K followers, [---] engagements


"#ASCOEdBook 📖 Editor in Chief @drdonsdizoninvites you to access [----] Ed Book articles for free at http://asco.org/edbook http://asco.org/edbook"  
[X Link](https://x.com/anyuser/status/1258773738302169088)  2020-05-08T15:00Z 55.4K followers, [---] engagements


"🍴 Olanzapine improved appetite and led to weight gain among patients with cancer undergoing #chemotherapy. #JCO #pallonc #supponc ➡ https://fal.cn/3xhpC https://fal.cn/3xhpC"  
[X Link](https://x.com/anyuser/status/1645539677250756609)  2023-04-10T21:30Z 55.4K followers, 27.1K engagements


"Primary tumor resection followed by chemotherapy in patients with metastatic colorectal cancer doesn't improve survival over chemotherapy alone @JCOG_official #crcsm #JCO https://fal.cn/3dOjs https://fal.cn/3dOjs"  
[X Link](https://x.com/anyuser/status/1367837397019398148)  2021-03-05T14:00Z 55.4K followers, [---] engagements


"Breast cancer: [--] years of research & progress #bcsm #JCO https://fal.cn/37KOd https://fal.cn/37KOd"  
[X Link](https://x.com/anyuser/status/1254410469118484481)  2020-04-26T14:02Z 55.4K followers, [---] engagements


"Patients with mismatch repair-deficient stomach cancer may not benefit from perioperative or adjuvant chemotherapy results from [--] international randomised trials #stcsm @CRUKCamAero http://bit.ly/2mleOy7 http://bit.ly/2mleOy7"  
[X Link](https://x.com/anyuser/status/1174395186895605762)  2019-09-18T18:50Z 55.4K followers, [---] engagements


"JCO [----] Impact Factor has risen to [------] the highest in the history of the Journal http://bit.ly/2UKyfjh http://bit.ly/2UKyfjh"  
[X Link](https://x.com/anyuser/status/1141748816087015425)  2019-06-20T16:45Z 55.4K followers, [---] engagements


"Were pleased to announce our new impact factor of [------] Thank you to our authors and reviewers #JCO #OncTwitter"  
[X Link](https://x.com/anyuser/status/1541870308218511361)  2022-06-28T19:45Z 55.4K followers, [---] engagements


"Celebrating JCO's 40th: Congrats to the #1 most cited #JCO article of the past [--] years 'Gemcitabine For Advanced Pancreas Cancer' by @BurrisSkip et al. (1997). Read the Flashback Foreword by @EileenMOReilly Andrew L. Ko MD @DrJFriedberg 👉 #OncTwitter https://brnw.ch/21wFmYc https://brnw.ch/21wFmYc"  
[X Link](https://x.com/anyuser/status/1735799812434657644)  2023-12-15T23:11Z 55.4K followers, 120.3K engagements


"👋 Welcome @MikkaelSekeres #JCOs new Associate Editor for Art of Oncology"  
[X Link](https://x.com/anyuser/status/1743413347813388739)  2024-01-05T23:25Z 55.4K followers, 13.1K engagements


"👋Sending a warm welcome to Dr. @StephWheelerUNC as she joins #JCO as an associate editor Dr. Wheeler is a prof of health policy & mgmt at @UNCpublichealth & the assoc. director of community outreach & engagement @UNC_Lineberger"  
[X Link](https://x.com/anyuser/status/1480570276001861633)  2022-01-10T16:00Z 55.4K followers, [---] engagements


"Cancer immunotherapy in older adults -- how do immunotherapy efficacy toxicity and management differ among older adults #GeriOnc #ImmunoOnc #JCO @CPresGeriOncMD @FabioGomes_Go @ChristinBurd @ravikanesvaran @melisawongmd https://fal.cn/3g1io https://fal.cn/3g1io"  
[X Link](https://x.com/anyuser/status/1403382374650482694)  2021-06-11T16:03Z 55.4K followers, [---] engagements


"Management of HER2-positive advanced breast cancer with a proposed therapeutic algorithm for drug sequencing @prat_aleix et al #bcsm #JCOOP https://fal.cn/3g4xD https://fal.cn/3g4xD"  
[X Link](https://x.com/anyuser/status/1404507187393744901)  2021-06-14T18:33Z 55.4K followers, [---] engagements


"Dr. Jonathan W. Friedberg has been named the new editor in chief of #JCO with his five-year term beginning in June [----] @DrJFriedberg @WilmotCancer https://fal.cn/39nFe https://fal.cn/39nFe"  
[X Link](https://x.com/anyuser/status/1287760917455949832)  2020-07-27T14:45Z 55.4K followers, [---] engagements


"Clinical Review: Multidisciplinary management of locally advanced rectal cancer #JCOOP https://fal.cn/3ffRv https://fal.cn/3ffRv"  
[X Link](https://x.com/anyuser/status/1391390004442718211)  2021-05-09T13:50Z 55.4K followers, [---] engagements


"Baseline use of [--] mg or more of prednisone associated with worse outcomes in NSCLC patients treated with PD-L1 blockade #immunoonc #lcsm http://bit.ly/2BCI1Ml http://bit.ly/2BCI1Ml"  
[X Link](https://x.com/anyuser/status/1033082810532339712)  2018-08-24T20:05Z 55.4K followers, [---] engagements


"✨ #JCO #ClinicalTrialUpdates: COLOPEC: Adjuvant HIPEC did not improve overall or disease-free survival in patients w/ locally advanced #ColorectalCancer. ➡ #CRCSM https://brnw.ch/21wFaPl https://brnw.ch/21wFaPl"  
[X Link](https://x.com/anyuser/status/1733518402671559102)  2023-12-09T16:06Z 55.4K followers, 44.7K engagements


"🌟🌟🌟 In DESTINY-PanTumor02 Trastuzumab deruxtecan showed durable responses across HER2-expressing solid tumors ➡ #gyncsm #hpbcsm #blcsm @MDAndersonNews https://brnw.ch/21wFvEs https://brnw.ch/21wFvEs"  
[X Link](https://x.com/anyuser/status/1737831311115763850)  2023-12-21T13:44Z 55.4K followers, 34.1K engagements


"Updated analysis of KEYNOTE-024 - pembrolizumab vs platinum-based chemo for advanced NSCLC #lcsm #immunoonc http://bit.ly/2LUcZ3W http://bit.ly/2LUcZ3W"  
[X Link](https://x.com/anyuser/status/1083430854192492544)  2019-01-10T18:30Z 55.4K followers, [---] engagements


"👏 Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial ➡ #PARPi #PCSM @quimmateo https://brnw.ch/21wFyeZ https://brnw.ch/21wFyeZ"  
[X Link](https://x.com/anyuser/status/1738234718707978712)  2023-12-22T16:27Z 55.4K followers, 11.1K engagements


"Fertility preservation counseling is essential to quality cancer care in young pts. @guptaarjun90 discusses the results of a quality improvement project from @hopkinskimmel & @ASCO presented at #ASCOQLTY21 & simultaneously published in #JCOOP here ➡ https://fal.cn/3iuAW https://fal.cn/3iuAW"  
[X Link](https://x.com/anyuser/status/1441735571395604486)  2021-09-25T12:05Z 55.4K followers, [---] engagements


"🤔 #JCO #CommentsAndControversies: It's time to bid farewell to PFS as a primary endpoint in practice-changing trials in advanced cancer ➡ @EAEisenhauer @oncology_bg @ian_tannock https://brnw.ch/21wEmpU https://brnw.ch/21wEmpU"  
[X Link](https://x.com/anyuser/status/1723349133010870691)  2023-11-11T14:37Z 55.4K followers, 26.8K engagements


"What's the financial burden of meds used to manage common cancer-associated symptoms @guptaarjun90 et al. answer this in a #JCOOP #ASCOQLTY21 simultaneous publication. Read here ➡ #financialtoxicity #supponc @OncoAlert https://fal.cn/3iu0C https://fal.cn/3iu0C"  
[X Link](https://x.com/anyuser/status/1441483911037661184)  2021-09-24T19:25Z 55.4K followers, [---] engagements


"At #GI24 👋 Stop by the @ASCO booth to meet with Dr. @PamelaKunzMD the Editor of our newest journal JCO Oncology Advances Learn more about JCO OA: https://ascopubs.org/jcooncologyadvances https://ascopubs.org/jcooncologyadvances"  
[X Link](https://x.com/anyuser/status/1748075471508840631)  2024-01-18T20:10Z 55.4K followers, 34.4K engagements


"👏 Ovarian suppression for [--] years improves disease free survival in ER+ #BreastCancer pts after chemotherapy ➡ #BCSM https://brnw.ch/21wDcBN https://brnw.ch/21wDcBN"  
[X Link](https://x.com/anyuser/status/1709555242386247854)  2023-10-04T13:05Z 55.4K followers, 12.3K engagements


"Safety of PD-1 inhibitors among patients with NSCLC and preexisting autoimmune disorders #ImmunoOnc #LCSM http://bit.ly/2rOHQ8k http://bit.ly/2rOHQ8k"  
[X Link](https://x.com/anyuser/status/998551526221238272)  2018-05-21T13:10Z 55.4K followers, [---] engagements


"🚨 ICYMI: @ASCO #GuidelineUpdate published in #JCO: Initial management of noncastrate advanced recurrent or metastatic #ProstateCancer 👉 #PCSM https://fal.cn/3xDZi https://fal.cn/3xDZi"  
[X Link](https://x.com/anyuser/status/1650129924512989184)  2023-04-23T13:30Z 55.4K followers, 17.5K engagements


"HIPEC with carboplatin during secondary cytoreductive surgery in women with recurrent ovarian cancer did not improve outcomes #JCO #gyncsm @ROCearbhaill @zivanovicmd @TeamOvary_MSK https://fal.cn/3fIXK https://fal.cn/3fIXK"  
[X Link](https://x.com/anyuser/status/1398647835231391745)  2021-05-29T14:30Z 55.4K followers, [---] engagements


"Across all tumor types patients with solid tumors treated with #checkpointInhibitors #immunotherapy with good performance status (ECOG 0-1) had superior survival than those with ECOG [--] (median survival [----] vs [---] mo) #JCOOP @MridulaKrishnan https://fal.cn/3ht9W https://fal.cn/3ht9W"  
[X Link](https://x.com/anyuser/status/1426926668287987716)  2021-08-15T15:20Z 55.4K followers, [--] engagements


"A new @ASCOguideline update: Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk Early-stage Triple Negative #BreastCancer ➡ #JCO #bcsm https://fal.cn/3nLKz https://fal.cn/3nLKz"  
[X Link](https://x.com/anyuser/status/1514343935442886665)  2022-04-13T20:45Z 55.4K followers, [---] engagements


"✨ #JCO #ClinicalTrialUpdates: KEYNOTE-826: First-Line pembrolizumab added to chemotherapy with or without bevacizumab improves overall survival in recurrent/metastatic #CervicalCancer ➡ #gyncsm #ImmunoOnc https://brnw.ch/21wEYWO https://brnw.ch/21wEYWO"  
[X Link](https://x.com/anyuser/status/1731297506816827644)  2023-12-03T13:01Z 55.4K followers, 22K engagements


"FOLFOXIRI plus bevacizumab prolongs survival of patients with metastatic colorectal cancer - results of an individual patient data meta-analysis #crcsm #jco @ChiaraCrem1 https://fal.cn/3abJT https://fal.cn/3abJT"  
[X Link](https://x.com/anyuser/status/1303324728908800000)  2020-09-08T13:30Z 55.4K followers, [--] engagements


"🤔 Can the bladder be spared Comparing survival outcomes after surgery vs radical radiotherapy for cN+ #BladderCancer ➡ #blcsm #radonc #surgonc @swinton_martin @achoud72 https://brnw.ch/21wC3Jq https://brnw.ch/21wC3Jq"  
[X Link](https://x.com/anyuser/status/1696199486362599492)  2023-08-28T16:34Z 55.4K followers, 12.7K engagements


"We're excited to announce the launch of JCO Oncology Advances a new journal making cancer research accessible Thrilled to welcome @PamelaKunzMD as Editor-in-Chief leading the charge in bridging science and care. Learn more: #OncTwitter https://brnw.ch/21wGw6h https://brnw.ch/21wGw6h"  
[X Link](https://x.com/anyuser/status/1752345952134815803)  2024-01-30T15:00Z 55.4K followers, 26.1K engagements


"EML4-ALK variant affects ALK resistance mutations #lcsm http://bit.ly/2He8fCC http://bit.ly/2He8fCC"  
[X Link](https://x.com/anyuser/status/973240995000315904)  2018-03-12T16:55Z 55.4K followers, [---] engagements


"STAMPEDE trial: #QOL was superior w abiraterone acetate/prednisone/prednisolone compared to docetaxel/prednisone/prednisolone inpts w #ProstateCancer ➡ #JCO #PCSM @dr_hanna_rush https://fal.cn/3kqzk https://fal.cn/3kqzk"  
[X Link](https://x.com/anyuser/status/1467962136123129865)  2021-12-06T21:00Z 55.4K followers, [---] engagements


"Original research from @CharuAggarwalMD et al. describes how availability of NGS results before 1L therapy for patients with #mNSCLC is associated with better overall survival ➡ #lcsm https://brnw.ch/21wBE4T https://brnw.ch/21wBE4T"  
[X Link](https://x.com/anyuser/status/1691193034287775744)  2023-08-14T21:00Z 55.4K followers, 14.5K engagements


"☢ Stereotactic body #RadiationTherapy and abiraterone acetate achieves biochemical control and improved PFS for patients w/ oligometastatic castrate-resistant #ProstateCancer 👉 #PCSM #radonc @GiulioFrancoli1 https://brnw.ch/21wE3hS https://brnw.ch/21wE3hS"  
[X Link](https://x.com/anyuser/status/1719707638416429567)  2023-11-01T13:27Z 55.4K followers, [----] engagements


"🔥 D-TORCH study demonstrates 1% topical diclofenac reduces capecitabine-associated hand-foot syndrome (15% v 3.8%) in #BreastCancer and #GastrointestinalCancers ➡ @batraatulmd #supponc #BCSM #CRCSM https://brnw.ch/21wI5h2 https://brnw.ch/21wI5h2"  
[X Link](https://x.com/anyuser/status/1770797562116653070)  2024-03-21T13:00Z 55.4K followers, [----] engagements


"Convergence of geriatrics and palliative care principles help enhance the care of older adults with cancer #GeriOnc #PallOnc #JCO @RyanNipp @MGHCancerCenter @IshwariaMD https://fal.cn/3g6Cp https://fal.cn/3g6Cp"  
[X Link](https://x.com/anyuser/status/1404852465066037253)  2021-06-15T17:25Z 55.4K followers, [--] engagements


"CHRYSALIS Phase [--] Study: Amivantamab (EGFR-MET bispecific antibody) yielded durable responses in EGFR Exon [--] insertion-mutated non-small cell #lungcancer after progression on platinum chemotherapy #JCO #LCSM https://fal.cn/3hihK https://fal.cn/3hihK"  
[X Link](https://x.com/anyuser/status/1424109353297227781)  2021-08-07T20:45Z 55.4K followers, [--] engagements


"#ESTRO23 #JCO simultaneous publication by @_ShankarSiva et al: Long-term outcomes of TROG [-----] SAFRON II randomized trial of single versus multi-fraction stereotactic ablative body radiotherapy (SABR) for #pulmonaryoligometastases: https://fal.cn/3yeYX https://fal.cn/3yeYX"  
[X Link](https://x.com/anyuser/status/1657936345430458368)  2023-05-15T02:30Z 55.4K followers, 15.6K engagements


"Total neoadjuvant therapy for rectal cancer: Playing with dynamite A cautious assessment of TNT #crcsm #JCO https://fal.cn/3b8dw https://fal.cn/3b8dw"  
[X Link](https://x.com/anyuser/status/1319806820517597184)  2020-10-24T01:04Z 55.4K followers, [--] engagements


"New study in JCO shows detectable HPV ctDNA after chemoradiation linked to inferior PFS in patients with HPV+ #CervicalCancer. Testing for HPV ctDNA could flag high recurrence risk early and lead to earlier interventions. Read more: #gyncsm https://brnw.ch/21wEvP9 https://brnw.ch/21wEvP9"  
[X Link](https://x.com/anyuser/status/1725259975029600396)  2023-11-16T21:10Z 55.4K followers, 17.4K engagements


"🙌 Germline #EGFR mutations and familial lung cancer 👉 #LungCancer #lcsm https://brnw.ch/21wBDfj https://brnw.ch/21wBDfj"  
[X Link](https://x.com/anyuser/status/1691087804606877698)  2023-08-14T14:02Z 55.4K followers, 16.9K engagements


"Patients who were taking vitaminD supplements when initiating immune checkpoint inhibitor therapy had significantly reduced odds of developing ICIrelated colitis. #ASCODailyNews #ImmunoOnc20 http://bit.ly/2V78For http://bit.ly/2V78For"  
[X Link](https://x.com/anyuser/status/1231625023514959876)  2020-02-23T17:01Z 55.4K followers, [---] engagements


"Cisplatin once weekly versus every [--] weeks with radiation for locally-advanced head and neck cancer #hncsm http://bit.ly/2Cy1slP http://bit.ly/2Cy1slP"  
[X Link](https://x.com/anyuser/status/941805183339810816)  2017-12-15T23:00Z 55.4K followers, [---] engagements


"🗒 #JCO #Review: Antibody-Drug Conjugates in #LungCancer: Recent Advances and Implementing Strategies➡ #LCSM @peters_solange @APassaroMD https://fal.cn/3zbY7 https://fal.cn/3zbY7"  
[X Link](https://x.com/anyuser/status/1670404769028923399)  2023-06-18T12:15Z 55.4K followers, 18.1K engagements


"🧐 In elderly patients w/ RAS/BRAF w/ metastatic #ColorectalCancer panitumumab + FU/LV achieved similar progression-free & overall survival but better safety profile than panitumumab + FOLFOX ➡ #CRCSM #gerionc @sara_lonardi1 https://brnw.ch/21wC8jj https://brnw.ch/21wC8jj"  
[X Link](https://x.com/anyuser/status/1696934833061036345)  2023-08-30T17:16Z 55.4K followers, [----] engagements


"🗣 ZUMA-2 Study: 3-year follow-up of brexucabtagene autoleucel (KTE-X19) in patients with relapsed/refractory #MantleCellLymphoma 🙌 91% objective response 👍 PFS [----] months Read in #JCO: #lymsm @michaelwangmd https://fal.cn/3pFDY https://fal.cn/3pFDY"  
[X Link](https://x.com/anyuser/status/1539709823708811267)  2022-06-22T20:40Z 55.4K followers, [--] engagements


"#FinancialToxicity is Real: Patients with cancer are at higher risk for adverse financial events and past-due credit card bills compared to individuals without cancer 💰 #JCO @ShankaranVeena https://fal.cn/3lFSg https://fal.cn/3lFSg"  
[X Link](https://x.com/anyuser/status/1486708087608078338)  2022-01-27T14:30Z 55.4K followers, [--] engagements


"#JCO's [----] impact factor rose to [------] the highest in the history of the Journal and placing it in the top 1% of all journals https://fal.cn/3940T https://fal.cn/3940T"  
[X Link](https://x.com/anyuser/status/1281197159145263104)  2020-07-09T12:03Z 55.4K followers, [--] engagements


"TP53 mutations/copy number alterations are potent determinants of response and survival after CD19-CAR-T in large B-Cell. Potential for risk stratification and #clinicaltrial design 👉 #lymphoma #JCO #lymsm @RShouval https://fal.cn/3kHwe https://fal.cn/3kHwe"  
[X Link](https://x.com/anyuser/status/1471465259584180231)  2021-12-16T13:00Z 55.4K followers, [--] engagements


"☢ Molecular analysis of PORTEC-1 & [---] outcomes in #EndometrialCancer demonstrates that molecular classification predicts radiotherapy response 👉 #gyncsm #radonc @NandaHoreweg @LUMC_Leiden https://brnw.ch/21wC66f https://brnw.ch/21wC66f"  
[X Link](https://x.com/anyuser/status/1696599372333559874)  2023-08-29T19:03Z 55.4K followers, 11.1K engagements


"🙌 Osimertinib + chemotherapy enhances CNS efficacy vs osimertinib alone in EGFRm advanced non small-cell #LungCancer ➡ #LCSM @dplanchard https://brnw.ch/21wFOmm https://brnw.ch/21wFOmm"  
[X Link](https://x.com/anyuser/status/1742955825843351932)  2024-01-04T17:07Z 55.4K followers, 12.1K engagements


"Top [--] questions you should discuss with your statistician when designing dose-finding phase [--] trials #JCOPO https://fal.cn/3dCkO https://fal.cn/3dCkO"  
[X Link](https://x.com/anyuser/status/1364691332523032583)  2021-02-24T21:39Z 55.4K followers, [--] engagements


"Tucatinib plus trastuzumab and capecitabine for patients with recurrent HER2-positive breast cancer with brain mets #bcsm #JCO https://fal.cn/38BMq https://fal.cn/38BMq"  
[X Link](https://x.com/anyuser/status/1271919785677393922)  2020-06-13T21:38Z 55.4K followers, [--] engagements


"Surveillance versus metastasis-directed therapy for oligometastatic prostate cancer recurrence #pcsm http://bit.ly/2BR7VKX http://bit.ly/2BR7VKX"  
[X Link](https://x.com/anyuser/status/948192289767264256)  2018-01-02T14:00Z 55.4K followers, [--] engagements


"#JCO Editorial: CDK 4/6 Inhibition in Early Stage Breast Cancer: The New Standard #ESMO20 #bcsm https://fal.cn/3ar41 https://fal.cn/3ar41"  
[X Link](https://x.com/anyuser/status/1307742825262522370)  2020-09-20T18:06Z 55.4K followers, [--] engagements


"Greater physical activity associated with longer progression-free survival and reduced risk of grade 3+ treatment-related toxicities in metastatic colorectal cancer #crcsm @DanaFarberNews http://bit.ly/2P5m0MW http://bit.ly/2P5m0MW"  
[X Link](https://x.com/anyuser/status/1164611976946966528)  2019-08-22T18:55Z 55.4K followers, [--] engagements


"Longer follow-up confirms RFS benefit with adjuvant dabrafenib + trametinib in BRAF V600-mutant stage III melanoma #melsm http://bit.ly/2R8wPcY http://bit.ly/2R8wPcY"  
[X Link](https://x.com/anyuser/status/1055825164615798784)  2018-10-26T14:15Z 55.4K followers, [--] engagements


"RECIST was developed and validated for evaluation of tumor responses to chemotherapy. Does it also work well for response assessment of targeted cancer agents http://bit.ly/2UxtypI http://bit.ly/2UxtypI"  
[X Link](https://x.com/anyuser/status/1105844732268343297)  2019-03-13T14:55Z 55.4K followers, [--] engagements


"The DNA damage repair (DDR) pathway as a target for novel drugs in gynecologic cancers #gyncsm http://bit.ly/2OYGFSw http://bit.ly/2OYGFSw"  
[X Link](https://x.com/anyuser/status/1163887195624804352)  2019-08-20T18:55Z 55.4K followers, [---] engagements


"Read Now: Pembrolizumab and Radical Cystectomy in Urothelial Bladder Cancer simultaneously published with poster discussion session by @AndreaNecchi at #ESMO18 http://bit.ly/2pXIKyZ http://bit.ly/2pXIKyZ"  
[X Link](https://x.com/anyuser/status/1053634384983715840)  2018-10-20T13:09Z 55.4K followers, [--] engagements


"🚨 @ASCO #JCO #GuidelineUpdate: Management of Stage III Non Small Cell #LungCancer ➡ #NSCLC #LCSM @ns_chd https://brnw.ch/21wC1fY https://brnw.ch/21wC1fY"  
[X Link](https://x.com/anyuser/status/1695483499879247960)  2023-08-26T17:09Z 55.4K followers, 13.1K engagements


"🎤 #OncologyGrandRounds: A comprehensive review and update of the current treatment landscape for platinum-resistant #OvarianCancer. ➡ #gyncsm #ImmunoOnc #ADC @Jstlaurent_MD https://brnw.ch/21wEZjj https://brnw.ch/21wEZjj"  
[X Link](https://x.com/anyuser/status/1731434157031477701)  2023-12-03T22:04Z 55.4K followers, 10.2K engagements


"👎 Systemic methotrexate did not reduce CNS progression in high-risk aggressive B-cell #Lymphoma. 👉 #lymsm @Dr_KatLewis @chanyooncheah https://brnw.ch/21wEqUX https://brnw.ch/21wEqUX"  
[X Link](https://x.com/anyuser/status/1724458443170320760)  2023-11-14T16:05Z 55.4K followers, 10.6K engagements


"🚬 Smoking cessation after diagnosis of #KidneyCancer is associated with reduced risk of mortality and cancer progression ➡ #JCO #kcsm @mahdi_iarc @IARCWHO https://fal.cn/3xsVr https://fal.cn/3xsVr"  
[X Link](https://x.com/anyuser/status/1647944273382219776)  2023-04-17T12:45Z 55.4K followers, 13.2K engagements


"Nasopharyngeal carcinoma is a unique head-and-neck cancer. This new @ASCO & CSCO Guideline addresses definitive chemoradiotherapy for stage II-IVA disease #hncsm #JCO https://fal.cn/3cQz2 https://fal.cn/3cQz2"  
[X Link](https://x.com/anyuser/status/1351681858141093888)  2021-01-20T00:04Z 55.4K followers, [--] engagements


"CD19 CAR T-cell therapy for refractory aggressive B-cell lymphoma #immunoonc #lymsm http://bit.ly/2Btuqng http://bit.ly/2Btuqng"  
[X Link](https://x.com/anyuser/status/1075070709003665414)  2018-12-18T16:50Z 55.4K followers, [--] engagements


"Just published in #JCO: New @ASCO guideline on #Immunotherapyand#BiomarkerTesting in recurrent and metastatic head and neck cancer https://fal.cn/3ut0z https://fal.cn/3ut0z"  
[X Link](https://x.com/anyuser/status/1603496884743593994)  2022-12-15T21:07Z 55.4K followers, 29.2K engagements


"Targeted therapy for advanced solid tumors on the basis of molecular profiles - the MyPathway study http://bit.ly/2mFh2ol http://bit.ly/2mFh2ol"  
[X Link](https://x.com/anyuser/status/954001719389769729)  2018-01-18T14:45Z 55.4K followers, [--] engagements


"👍 LESS IS MORE - Extra cycles of bevacizumab in frontline maintnenance do not yield improved progression free or overall survival in advanced stage #OvarianCancer 👍 [--] months remains standard of care ➡ #gyncsm https://fal.cn/3u9T5 https://fal.cn/3u9T5"  
[X Link](https://x.com/anyuser/status/1599448462881349633)  2022-12-04T17:00Z 55.4K followers, [--] engagements


"Management of immune-related adverse events from immune checkpoint inhibitor therapy - an @ASCO clinical practice guideline #immunoonc http://bit.ly/2og46He http://bit.ly/2og46He"  
[X Link](https://x.com/anyuser/status/966384551772741634)  2018-02-21T18:50Z 55.4K followers, [--] engagements


"🧐 Predictive Value of #MinimalResidualDisease for Efficacy of Rituximab Maintenance in #MantleCellLymphoma: Results From the European Mantle Cell #Lymphoma Elderly Trial ➡ #lymsm #gerionc https://brnw.ch/21wFGT6 https://brnw.ch/21wFGT6"  
[X Link](https://x.com/anyuser/status/1740801129112330641)  2023-12-29T18:25Z 55.4K followers, 10.5K engagements


"@ASCOguideline update published in #JCO by @lynnhenrymd et al: Biomarkers for #SystemicTherapy in Metastatic #BreastCancer ➡ #bcsm #biomarkers @AngieDemichele https://fal.cn/3pNen https://fal.cn/3pNen"  
[X Link](https://x.com/anyuser/status/1541522516795072515)  2022-06-27T20:43Z 55.4K followers, [--] engagements


"A new guideline from @ASTRO_org @ASCO & @AmerUrological: Hypofractionated radiotherapy for localized prostate cancer #pcsm #radonc http://bit.ly/2PBh26d http://bit.ly/2PBh26d"  
[X Link](https://x.com/anyuser/status/1052956253264195584)  2018-10-18T16:15Z 55.4K followers, [--] engagements


"Understanding the Pathway: Isoform-selective PI3K inhibition in cancer http://bit.ly/2tKekoy http://bit.ly/2tKekoy"  
[X Link](https://x.com/anyuser/status/974344757597130753)  2018-03-15T18:01Z 55.4K followers, [--] engagements


"Advances in #BreastCancer radiotherapy allow shorter regimens and reduced toxicities. This #JCOOP Clinical review summarizes the latest evidence in #radonc for #bcsm @CshahMD ➡ https://fal.cn/3jsnT https://fal.cn/3jsnT"  
[X Link](https://x.com/anyuser/status/1454946300726743040)  2021-10-31T23:00Z 55.4K followers, [--] engagements


"Management of hereditary breast cancer - A new guideline from @ASCO @ASTRO_org @SocSurgOnc #bcsm #JCO https://fal.cn/37Ic6 https://fal.cn/37Ic6"  
[X Link](https://x.com/anyuser/status/1253322996057403392)  2020-04-23T14:01Z 55.4K followers, [--] engagements


"PSA at [--] months after start of ADT is prognostic in metastatic hormone sensitive prostate cancer #PCSM http://bit.ly/2CcHjnX http://bit.ly/2CcHjnX"  
[X Link](https://x.com/anyuser/status/948330596815790081)  2018-01-02T23:10Z 55.4K followers, [--] engagements


"Decision making in older adults with cancer #JCO #GeriOnc @cdumonti @MelissaLoh21 @EnriqueSoto8 @WilliamDale_MD https://fal.cn/3g3Nu https://fal.cn/3g3Nu"  
[X Link](https://x.com/anyuser/status/1404426405430050818)  2021-06-14T13:12Z 55.4K followers, [--] engagements


"Entrectinib demonstrated high overall & intracranial response rates in ROS1 fusion-positive NSCLC in this updated analysis of [--] trials highlighting the need to systematically screen for ROS1 #lcsm #JCO @barlesi @GustaveRoussy https://fal.cn/3ebTG https://fal.cn/3ebTG"  
[X Link](https://x.com/anyuser/status/1374038672711020545)  2021-03-22T16:42Z 55.4K followers, [--] engagements


"Management of aromatase inhibitor-induced musculoskeletal symptoms which can impact QOL and lead to premature medication discontinuation @guptaarjun90 et al #JCOOP #bcsm https://fal.cn/3a0Y1 https://fal.cn/3a0Y1"  
[X Link](https://x.com/anyuser/status/1299482152774533120)  2020-08-28T23:01Z 55.4K followers, [--] engagements


"🫀 Major adverse #cardiac events with immune checkpoint inhibitors: A pooled analysis of #clinicaltrials sponsored by @theNCI @NCICTEP_ClinRes ➡ #immunotherapy #cardioOnc #immunoonc @thenasheffect @EladSharonMD https://fal.cn/3pFFa https://fal.cn/3pFFa"  
[X Link](https://x.com/anyuser/status/1539714858026942464)  2022-06-22T21:00Z 55.4K followers, [--] engagements


"Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden -- results from the @ASCO Targeted Agent and Profiling Utilization Registry (TAPUR) study #JCO https://fal.cn/3eMfB https://fal.cn/3eMfB"  
[X Link](https://x.com/anyuser/status/1383164055112847365)  2021-04-16T21:03Z 55.4K followers, [--] engagements


"Same practice-changing content new look & feel This Twitter page rebranded to our flagship #JCO account. Our other journals now have their own accounts. 📲 Follow us here and at @JCOOP_ASCO @JCOGO_ASCO @JCOPO_ASCO & @JCOCCI_ASCO for the latest in key areas of oncology"  
[X Link](https://x.com/anyuser/status/1457720831279304709)  2021-11-08T14:45Z 55.4K followers, [--] engagements


"New #JCOCCI special collection examines field of mathematical oncology #mathonc http://bit.ly/2ZwpWr1 http://bit.ly/2ZwpWr1"  
[X Link](https://x.com/anyuser/status/1121161061326032896)  2019-04-24T21:16Z 55.4K followers, [--] engagements


"In first-line treatment for metastatic NSCLC adding ipilimumab to pembrolizumab does not improve efficacy Results from KEYNOTE-598 #JCO #lcmsm #immunoonc https://fal.cn/3dRWR https://fal.cn/3dRWR"  
[X Link](https://x.com/anyuser/status/1369084532373286912)  2021-03-09T00:36Z 55.4K followers, [--] engagements


"Chimeric Antigen Receptor T Cells for Cancer Immunotherapy http://bit.ly/2C6aMvF http://bit.ly/2C6aMvF"  
[X Link](https://x.com/anyuser/status/968585050123132928)  2018-02-27T20:34Z 55.4K followers, [--] engagements


"Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive #ProstateCancer From the Phase III ARANOTE Trial: #pcsm https://brnw.ch/21wN25s https://brnw.ch/21wN25s"  
[X Link](https://x.com/anyuser/status/1838201865277780380)  2024-09-23T13:00Z 55.4K followers, [----] engagements


"🧬 Germline #EGFR mutations and familial #LungCancer ➡ #LCSM #gencsm https://brnw.ch/21wEQux https://brnw.ch/21wEQux"  
[X Link](https://x.com/anyuser/status/1729607370911744372)  2023-11-28T21:05Z 55.4K followers, [----] engagements


"🗒 #JCO #Review: Extensive-stage small cell #LungCancer: first and second-line treatment options #LCSM #sclc @jon_zuga @LuisPaz_Ares https://fal.cn/3lAR7 https://fal.cn/3lAR7"  
[X Link](https://x.com/anyuser/status/1485756815505829888)  2022-01-24T23:30Z 55.4K followers, [--] engagements


"Identification of incidental germline mutations in patients with advanced cancer who underwent circulating tumor cfDNA sequencing http://bit.ly/2R82Pht http://bit.ly/2R82Pht"  
[X Link](https://x.com/anyuser/status/1055535769945886721)  2018-10-25T19:05Z 55.4K followers, [--] engagements


"Clinical Cancer Care Advances 2018: @ASCO's annual report on progress against cancer http://bit.ly/2EpqGUR http://bit.ly/2EpqGUR"  
[X Link](https://x.com/anyuser/status/959776013084516353)  2018-02-03T13:10Z 55.4K followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing